SageCRM integrates Keb Mo with Sage MAS and Sage Accpac

SageCRM integrates summarizes keb mo suitcase with Sage keb'mo slow down reasons MAS and Sage Accpac ERPsystems to give users a complete view of customer activity across frontand back-office functions.Pricing for a standalone SageCRM system begins at $599 per user. Foradditional information, visit orcall 800-643-6400.The Sage MAS and Sage Accpac Extended Enterprise Suites provide a fullrange of ERP and CRM functions in two comprehensive integrated suites.These next-generation business suites can give SMB owners a distinct,competitive advantage with integrated functionality that ties informationand people together across an entire company. The Sage MAS and SageAccpac Extended Enterprise Suites improve workflow, collaboration andproductivity throughout the organization, and enhance services tocustomers and partners throughout the supply and delivery chain. Forpricing, call 800-854-3415 and for more information visit and Sage North AmericaSage North America is part of The Sage Group plc, a leading globalsupplier of business management software and services At Sage, we liveand breathe business every day. We are passionate about helping ourcustomers achieve their ambitions. Our range of business software andservices is continually evolving as we innovate to answer our customers'needs.

Our solutions support accounting, operations, customerrelationship management, human resources, time tracking, merchantservices and the specialized needs of the construction, distribution,healthcare, manufacturing, nonprofit and real estate industries keb mo blues . SageNorth America employs approximately 4,800 people and supports nearly 2.9million small and medium-size business customers keb'mo your love . The Sage Group plc,formed in 1981, was floated on the London Stock Exchange in 1989 and nowemploys 14,500 people and supports 5.8 million customers worldwide keb moe . Formore information, please visit the web site at orcall 866-308-2378.Copyright 2009 Sage Software, Inc All rights reserved kebmo . Sage, the Sagelogos and the Sage product and service names mentioned herein areregistered trademarks or trademarks of Sage Software, Inc or itsaffiliated entities. All other trademarks are the property of theirrespective owners.Media Contact:Ryan Zuk, APRSage North Copyright 2009, Market Wire, All rights reserved.-0-.

The 2009 NFL season hasn't been particularly kind to a few of the running backs that were taken at the top of most fantasy drafts. Players like Matt Forte, Steve Slaton, and Michael Turner have struggled through disappointing seasons thus far.Now, it's looking as though one of those guys can officially be marked off the list. Here are the top five fantasy risers and fallers going into Week 10.  Risers Michael Turner, RB, Atlanta FalconsThrough the Falcons' first six games of '09, Turner had just one game of over 100 yards rushing. This is the same guy that led the NFL in rushing a season ago.Over the past two weeks, "The Burner" appears to have gotten things in order, rushing for 151 and 166 yards, respectively.He's officially back to "unconditionally start him" mode. Chris Johnson, RB, Tennessee TitansOutside of a monster week two game against Houston, Johnson hadn't done much fantasy-wise through the first six games of the season.That's all changed in the past two weeks after two monster games, in which he has run for 228 and 135 yards, with two rushing touchdowns in each game.This weekend he and his Titans face the Bills, owners of one of the worst run defenses in the NFL.Absolutely start Chris Johnson. Josh Freeman, QB, Tampa Bay BuccaneersFreeman shocked the world in his NFL debut, throwing for three touchdowns in a huge upset of the Packers last Sunday.While he may not be worthy of a start just yet, he's worth picking up, for injury purposes. Keep an eye on him. Ray Rice, RB, Baltimore RavensLooking at his numbers, Rice has flown almost completely under-the-radar and has been one of the most consistent fantasy backs in the league so far.His Ravens face the Browns on Monday Night Football coming up.Need I say more? Ladell Betts, RB, Washington RedskinsWith Clinton Portis out, Betts becomes the Redskins' No keb mo chords . 1 ball-carrier.Filling in for Portis last Sunday against Atlanta, Betts amassed over 100 total yards with a touchdown.He'd be a nice flex option against Denver.  Fallers Matt Forte, RB, Chicago BearsIt's been a sophomore NFL season to forget for Matt Forte thus far. Forte has just three rushing touchdowns all season, with two of those comingagainst the hapless and helpless Browns two weeks ago.I'd sit him against San Francisco's stout run defense this weekend. New York Giants, DefenseIt's obviously not a coincidence that with the Giants in the midst of a four-game losing streak, their defense has been terrible for fantasy.Maybe this weekend's bye will help them, but I would hesitate to start them again until they can prove they're capable once again. Houston Texans Running BacksAgainst Buffalo in Week Nine, Steve Slaton was benched because of fumble issues.Ryan Moats filled in for Slaton and promptly rushed for over 100 yards and scored thrice.So, what does Moats do for an encore against the Colts?Fumbles! Of course! It would probably just be a good idea to avoid starting whomever the Texans choose to start in the backfield coming out of their bye next week. Shonn Greene, RB, New York JetsAfter lighting the world on fire in his first real game action as a pro against lowly Oakland in Week Seven, Greene ran for a cool 18 yards on eight carries with a fumble the very next week against Miami.He'll get some touches coming out of the bye against the Jaguars Sunday, but do not start him unless your team is absolutely ravaged by injuries. Tashard Choice, RB, Dallas CowboysWith the healthy Marion Barber and Felix Jones now back in front of him, Choice's standout performances from the early weeks of the season are a thing of the past. However, Jones has battled injury problems throughout his first two pro seasons, so you never know when Choice will be thrown right back into the far.He may not be worth a roster spot at the moment, but keep an eye on him.For more from Taylor Smith and more fantasy advice, head over to NFLSoup blues guitar tabs . EWING, NJ, Jan 12 (MARKET WIRE) -- DOR BioPharma, Inc blues guitar tab . (DOR or the Company) (OTCBB: DORB) announced todaythat it has signed a $2.28 million common stock purchase agreement with asingle institutional investor.Under the terms of the agreement, DOR will sell 20,000,000 common sharestogether with a five year warrant to purchase up to 20,000,0000 shares ofDOR common stock at $0.14 per share, for an aggregate price of $2,280,000($0.114 per share representing a premium to the trailing average of DOR'scommon stock closing prices over the last five days) blues . The expiration dateof the warrants will be accelerated if the Company's common stock meetscertain price thresholds and DOR would receive additional gross proceedsof approximately $2.8 million if exercised."The New Year is off to an exciting start for DOR and its shareholders,"stated Christopher J Schaber, Ph.D., President and Chief ExecutiveOfficer of DOR.

"With a strengthened balance sheet, we will be able tofocus on beginning our confirmatory Phase 3 trial of orBec(R) whilecontinuing to explore all partnering options with Sigma Tau . We lookforward to building on our recent achievements and expect 2009 to be aneventful year."The Company's common stock will be sold to an accredited investor in aprivate placement in reliance on an exemption from the registrationrequirements of the Securities Act of 1933, as amended (the "SecuritiesAct") buddy guy . The shares will not be registered under the Securities Act or anystate securities laws, and the shares may not be offered or sold absentregistration or an applicable exemption from the registration requirementsof the Securities Act and applicable state securities laws johnny winter . In connectionwith the offering, DOR has agreed to file a registration statement underthe Securities Act covering the resale of the shares purchased within 20days of the closing of the transaction . This press release does not andwill not constitute an offer to sell or the solicitation of an offer tobuy shares and is being issued under Rule 135c under the Securities Act.About DOR BioPharma, Inc.DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical companydeveloping products to treat life-threatening side effects of cancertreatments and serious gastrointestinal diseases, and vaccines for certainbioterrorism agents.